In the past decade, an exciting realization has been that diverse liver diseases—ranging
from nonalcoholic steatohepatitis, alcoholic steatohepatitis and cirrhosis to hepatocellular …

Alcoholic liver disease, which ranges from mild disease to alcoholic hepatitis and cirrhosis,
is a leading cause of morbidity and mortality worldwide. Alcohol intake can lead to changes …

Hepatocellular carcinoma (HCC) is the third leading cause of worldwide cancer mortality.
HCC almost exclusively develops in patients with chronic liver disease, driven by a vicious …

The human gut microbiome has emerged as a major player in human health and disease.
The liver, as the first organ to encounter microbial products that cross the gut epithelial …

Bacterial infections are frequent in cirrhotic patients with acute decompensation or acute-on-
chronic liver failure and can complicate the clinical course. Delayed diagnosis and …

NAFLD is the most prevalent form of liver disease in the USA, affecting an estimated 30% of
the population. The condition is associated with increased mortality related to cardiovascular …

Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and
broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative …

Chronic liver diseases are a major cause of morbidity and mortality worldwide. Recently, gut
dysbiosis was identified as an important factor in the pathogenesis of liver diseases. The …

The liver is one of the major metabolic organs in the body, susceptible to injury caused by
various factors. In response to injury, sophisticated mechanisms are engaged to repair and …

Gut microbiota is a microecosystem composed of various microorganisms. It plays an
important role in human metabolism, and its metabolites affect different tissues and organs …